IRS1 and Alzheimer disease: It has been shown that dysregulation of the expression of GLP-1 and GIP receptors and impairment of insulin receptor substrate 1 (IRS-1) are implicated in the development and progression of neurodegenerative diseases such as Alzheimer’s disease (AD) (Talbot et al. 2012).